Hudson Bay Capital Management
JBIO

Hudson Bay Capital Management’s Jade Biosciences JBIO Stock Holding History

Hudson Bay Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,943
Closed -$2.33M – 730
2023
Q4 		$2.33M Buy
+2,943
New +$1.5M 0.01% 425

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management's JBIO Position: Q1 2024 in Review

Hudson Bay Capital Management sold out of Jade Biosciences (JBIO) in Q1 2024, closing a stake of 2,943 shares — an estimated $2.33M sold.

Hudson Bay Capital Management first reported a position in JBIO in Q4 2023 and held it in 1 quarter. The position peaked at $2.33M in Q4 2023. 77 funds tracked by Wall St. Rank hold JBIO as of Q1 2024.

  • Hudson Bay Capital Management reported no remaining Jade Biosciences position as of Q1 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 2,943 Jade Biosciences shares in Q1 2024, an estimated $2.33M.
  • Hudson Bay Capital Management first reported a position in Jade Biosciences in Q4 2023 and held it in 1 quarter.
  • Hudson Bay Capital Management's Jade Biosciences position peaked at $2.33M in Q4 2023.
  • 77 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2024.

Based on Hudson Bay Capital Management's 13F filing for Q1 2024, filed 15 May 2024.